Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2.

Kriti Negi, Meetu Agarwal, Isha Pahuja, Bhavya Bhardwaj, Mansi Rawat, Ashima Bhaskar, Ved Prakash Dwivedi
{"title":"Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2.","authors":"Kriti Negi,&nbsp;Meetu Agarwal,&nbsp;Isha Pahuja,&nbsp;Bhavya Bhardwaj,&nbsp;Mansi Rawat,&nbsp;Ashima Bhaskar,&nbsp;Ved Prakash Dwivedi","doi":"10.1093/oxfimm/iqad001","DOIUrl":null,"url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes lethal coronavirus disease (COVID-19). SARS-CoV-2 has been the chief source of threat to public health and safety from 2019 to the present. SARS-CoV-2 caused a sudden and significant rise in hospitalization due to respiratory issues and pneumonia. We are consistently uncovering new information about SARS-CoV-2, and yet so much is to explore to implement efficient interventions to combat the emergent variants and spread of the ongoing pandemic. Information regarding the existing COVID-19 pandemic is streamlining continuously. However, clinical symptoms of SARS-CoV-2 infections spanning from asymptomatic infection to severe death-instigating disease remain consistent with preliminary reports. In this review, we have briefly introduced highlights of the COVID-19 pandemic and features of SARS-CoV-2. We have focused on current knowledge of innate and adaptive immune responses during SARS-CoV-2 infections and persisting clinical features of recovered patients. Furthermore, we have discussed how these immune responses are not tightly regulated and imbalance can direct the latter phases of COVID-19, long-COVID symptoms, and cause detrimental immunopathogenesis. COVID-19 vaccines are also discussed in detail to describe the efforts going around the world to control and prevent the infection. Overall, we have summarized the current knowledge on the immunology of SARS-CoV-2 infection and the utilization of that knowledge in the development of a suitable COVID-19 therapeutics and vaccines.</p>","PeriodicalId":74384,"journal":{"name":"Oxford open immunology","volume":"4 1","pages":"iqad001"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985161/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oxford open immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/oxfimm/iqad001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes lethal coronavirus disease (COVID-19). SARS-CoV-2 has been the chief source of threat to public health and safety from 2019 to the present. SARS-CoV-2 caused a sudden and significant rise in hospitalization due to respiratory issues and pneumonia. We are consistently uncovering new information about SARS-CoV-2, and yet so much is to explore to implement efficient interventions to combat the emergent variants and spread of the ongoing pandemic. Information regarding the existing COVID-19 pandemic is streamlining continuously. However, clinical symptoms of SARS-CoV-2 infections spanning from asymptomatic infection to severe death-instigating disease remain consistent with preliminary reports. In this review, we have briefly introduced highlights of the COVID-19 pandemic and features of SARS-CoV-2. We have focused on current knowledge of innate and adaptive immune responses during SARS-CoV-2 infections and persisting clinical features of recovered patients. Furthermore, we have discussed how these immune responses are not tightly regulated and imbalance can direct the latter phases of COVID-19, long-COVID symptoms, and cause detrimental immunopathogenesis. COVID-19 vaccines are also discussed in detail to describe the efforts going around the world to control and prevent the infection. Overall, we have summarized the current knowledge on the immunology of SARS-CoV-2 infection and the utilization of that knowledge in the development of a suitable COVID-19 therapeutics and vaccines.

Abstract Image

Abstract Image

Abstract Image

应对COVID-19大流行的挑战:洞察SARS-CoV-2的分子机制、免疫反应和治疗方法。
严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)感染会导致致命的冠状病毒病(COVID-19)。从2019年到现在,SARS-CoV-2一直是公共卫生和安全的主要威胁来源。由于呼吸系统问题和肺炎,SARS-CoV-2导致住院人数突然大幅上升。我们不断发现关于SARS-CoV-2的新信息,但要实施有效的干预措施,以对抗新出现的变体和持续大流行的传播,还有很多工作要探索。有关当前COVID-19大流行的信息正在不断精简。然而,从无症状感染到严重致死疾病的SARS-CoV-2感染的临床症状与初步报告保持一致。本文简要介绍了2019冠状病毒病大流行的要点和SARS-CoV-2的特点。我们的重点是目前对SARS-CoV-2感染期间的先天性和适应性免疫反应的了解以及康复患者的持续临床特征。此外,我们还讨论了这些免疫反应如何不受严格调节,不平衡如何指导COVID-19的后期阶段,长期的COVID-19症状,并导致有害的免疫发病机制。还详细讨论了COVID-19疫苗,以描述世界各地为控制和预防感染所做的努力。总的来说,我们总结了目前关于SARS-CoV-2感染的免疫学知识以及在开发合适的COVID-19治疗方法和疫苗中的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.20
自引率
0.00%
发文量
0
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信